Search Results
Jan 20, 2026, 08:42 ET DISC Surgery Center at Tarzana Opens as AAAHC-Accredited Ambulatory Surgery Center
focus on advanced spine, joint, and interventional pain care, including motion-preservation techniques, the purpose-built ambulatory surgery center (ASC) has earned full
More news about: TriasMD
Jan 20, 2026, 05:00 ET 歌禮選定新一代每月一次皮下注射GLP-1R/GIPR/GCGR三靶點激動劑多肽ASC37進行臨床開發
formulation）的平均表觀半衰期約為17天，是retatrutide在標準液體劑型下的7倍。ASC37注射劑在體外激動活性和表觀半衰期方面均優於retatrutide，這些優勢表明其有望成為新一代肥胖症療法。「我們正在推進一款有望實現更強藥效、支持每月一次給藥的新一代三靶點激動劑ASC37進入臨床階段，」歌禮創始人、董事會主席兼首席執行官吳勁梓博士表示，「我們的這項I期研究預計將於 2026年下半年開展，將是我們向改善肥胖人群治療選擇這一全面戰略邁進的又一步。」ASC37注射劑潛在聯合療法研究ASC37注射劑正在作為單藥及
More news about: 歌禮製藥有限公司
Jan 20, 2026, 04:00 ET Ascletis Selects a Next-Generation Once-Monthly Subcutaneously Administered GLP-1R/GIPR/GCGR Triple Peptide Agonist, ASC37, for Clinical Development
AISBDD and ULAP technologies enable the Company to design, optimize and develop multiple once-monthly SQ ultra-long-acting peptides, including ASC35, ASC36 and ASC37. Based on the properties of peptides, the Company can design, through its proprietary ULAP technology, various slow-release constants (k)
More news about: Ascletis Pharma Inc.
Jan 14, 2026, 13:46 ET Innovations Surgery Center Becomes First Ambulatory Surgery Center in Mid-Atlantic Region to Offer Robotic-Assisted Gynecologic Surgery
https://innovativegyn.com/locations/visionary-asa-rockville-md/About Visionary ASCVisionary ASC is a national ambulatory surgery center platform designed to support minimally invasive specialists practicing value-based care. By developing and operating purpose-built outpatient surgery centers, Visionary ASC expands access to advanced surgical
More news about: Visionary ASC
Jan 13, 2026, 09:00 ET Tropical Cheese Industries Acquires Cibao Meat Products
Frank, Wilkinson Brimmer Katcher212.355.4449AUA Media ContactMax RaydenSenior DirectorASC Advisors LLCTel: 203 992 1227Cell: 917 705 1970Email: [email protected]
More news about: Tropical Cheese
Jan 07, 2026, 10:00 ET World's Strongest Man Hafþór "Thor" Björnsson to Attempt Record-Breaking Lift at the Enhanced Games
times.Thor is also the only man to achieve the elusive Strongman Triple Crown, winning World's Strongest Man (WSM), the Arnold Strongman Classic (ASC), and Europe's Strongest Man (ESM) in the same year (2018).As an actor, Björnsson is best known for his portrayal of Ser Gregor "The Mountain"
More news about: Enhanced
Jan 05, 2026, 08:47 ET COMPASS SURGICAL PARTNERS NAMES MARK LANGSTON CHIEF EXECUTIVE OFFICER
sustainable, strong ambulatory surgery center (ASC) networks. For physician partners, Compass delivers proven pathways to ASC ownership, operational excellence, and long-term value. Health systems rely on Compass to scale surgical care efficiently — advancing ASC growth within core service areas and reaching
More news about: Compass Surgical Partners
Jan 04, 2026, 19:10 ET Ascletis Announces U.S. FDA IND Clearance for 13-Week Phase II Study of Its Oral Small Molecule GLP-1, ASC30, in Participants with Diabetes
and 80 mg ASC30 tablets and matching placebo tablets, respectively. ASC30 will be titrated weekly from 1 mg to target doses of 40 mg, 60 mg and 80 mg. Enrollment is expected to begin in the first quarter of 2026. Ascletis recently completed its 13-week Phase II study evaluating ASC30, an oral small
More news about: Ascletis Pharma Inc.
Jan 04, 2026, 19:10 ET 歌禮宣佈其口服小分子GLP-1，ASC30，在糖尿病受試者中的13周II期研究IND獲美國FDA批准
歌禮製藥有限公司（香港聯交所代碼：1672，簡稱「歌禮」）今日宣佈，近期已獲得美國食品藥品監督管理局（FDA）對其口服小分子GLP-1，ASC30，在糖尿病受試者中的II期研究的新藥臨床試驗（IND）的批准。該II期研究是一項為期13周、隨機、雙盲、安慰劑對照及多中心的研究，旨在評估ASC30在2型糖尿病受試者中的療效、安全性和耐受性。該II期研究的主要終點是至13周時，治療組與安慰劑組相比，糖化血紅蛋白（HbA1c）相對基線的平均變化。次要終點包括：至13周時，治療組與安慰劑組相比，空腹血糖相對基線的平均變化；至13周時，治療組與安慰劑組相比，體重相對基線的平均變化；以及安全性和耐受性。該II期研究將在美國多個中心入組約100例2型糖尿病的受試者。受試者將被按約2:3:3:2的比例，分別隨機分配至40毫克、60毫克和80毫克的ASC30片治療組及匹配的安慰劑組。ASC30將從1毫克開始，每周滴定（titrated
More news about: 歌禮製藥有限公司
Dec 29, 2025, 13:28 ET Tri-City Cardiology's Ambulatory Surgical Center Surpasses 6,000 Procedures, Marking a Major Milestone in Outpatient Cardiovascular Care
their care," said Bruce Stec, ASC administrator at Tri-City Cardiology. "Delivering more than 6,000 procedures in an outpatient environment speaks to the strength of our team, the sophistication of our facility, and our commitment to cardiovascular treatment."The ASC offers a comprehensive range
More news about: Tri-City Cardiology
Dec 17, 2025, 16:53 ET Defender Capital Reiterates Intention to Vote AGAINST STAAR Surgical's Proposed Sale to Alcon Inc.
individuals, families, and corporations. We take a research driven, long-term approach, investing in U.S. equities.Media Contact:ASC AdvisorsTaylor Ingraham (203 992 1230)[email protected]
More news about: Defender Capital
Dec 16, 2025, 13:53 ET The Surgery Center of Rhode Island Recognized as Leapfrog Top Ambulatory Surgery Center for Third Consecutive Year
quality in the nation. Leapfrog assesses the safety and quality of ASCs based on national, evidence-based measures. Surgery centers named to the "Top ASC" list are recognized for exceptional clinical outcomes, adherence to best practices aimed at preventing patient harm, and high performance across patient
More news about: Constitution Surgery Alliance
Dec 16, 2025, 13:14 ET OrthAlign Expands Lantern® Hip Platform to Support Posterior-Based Surgical Approaches in Total Hip Arthroplasty
enhances both efficiency in the OR and consistency for my patients," said Dr. McLaughlin.Lantern Hip is an accessible option for any hospital or ASC. Its capital-free model and portable design, paired with its clinical accuracy and precision, make it an attractive alternative to large-footprint robots.
More news about: OrthAlign
Dec 16, 2025, 13:00 ET Advita Ortho Wins Innovation Award for Soft Tissue Balancing in Knee Replacement Surgery
replacements.8Backed by five granted patents, Newton lays the groundwork for future AI-powered workflows that extend beyond knee arthroplasty. The system's compact, ASC-friendly design delivers these capabilities without the capital investment or annual maintenance burden associated with competing robotic platforms.
More news about: Advita Ortho, LLC
Dec 16, 2025, 08:30 ET Eight Constitution Surgery Alliance Facilities Recognized Nationally as Leapfrog "Top Ambulatory Surgery Centers" for Excellence in Safety and Quality
Connecticut Surgery Center have earned Leapfrog's "Top ASC" designation for two consecutive years. "At CSA, our mission has always been rooted in clinical quality," said Kris Mineau, CSA Founder and CEO. "Receiving multiple Leapfrog Top ASC recognitions year after year affirms the dedication, skill,
More news about: Constitution Surgery Alliance
Dec 16, 2025, 08:30 ET Orthopedic Associates Surgery Center in Rocky Hill, CT Earns Leapfrog "Top Ambulatory Surgery Center" Designation for Third Consecutive Year
outpatient surgery centers, is proud to announce that Orthopedic Associates Surgery Center (OASC) has been named a Leapfrog Top Ambulatory Surgery Center (ASC) for 2025, marking the third consecutive year the center has earned this prestigious national recognition. Just 37 ASCs nationwide achieved this distinction,
More news about: Constitution Surgery Alliance
Dec 16, 2025, 08:30 ET 5 Hartford HealthCare ambulatory surgery centers recognized nationally with Leapfrog award
2025 from Leapfrog, an independent organization widely regarded as the nation's leading advocate for patient safety and transparency. Leapfrog's Top ASC award recognizes efforts in staffing, hand hygiene compliance, patient experience, infection prevention and practices for safer surgery and error prevention."This
More news about: Constitution Surgery Alliance
Dec 16, 2025, 08:30 ET East Bay Surgery Center Named a Leapfrog "Top Ambulatory Surgery Center" for 2025
quality in the nation. Leapfrog assesses the safety and quality of ASCs based on national, evidence-based measures. Surgery centers named to the "Top ASC" list are recognized for exceptional clinical outcomes, adherence to best practices aimed at preventing patient harm, and high performance across patient
More news about: Constitution Surgery Alliance
Dec 15, 2025, 16:02 ET Costs of Care and The Leapfrog Group Honor Hartford HealthCare CEO Jeffrey A. Flaks with Steven Schroeder Award for Outstanding Healthcare Leadership
Leapfrog Ambulatory Surgery Center (ASC) Survey collect and transparently report hospital and ASC performance, empowering purchasers to find the highest-value care and giving consumers the lifesaving information they
More news about: Hartford HealthCare
Dec 15, 2025, 09:10 ET The Leapfrog Group Announces 2025 Top Hospitals and Top ASCs
Top Ambulatory Surgery Center (ASC) Award. This national recognition is one of the most competitive honors U.S. hospitals and surgery centers can earn for excellence in patient safety
More news about: The Leapfrog Group
Dec 15, 2025, 04:00 ET Ascletis Announces Positive Topline Results from U.S. Phase I Study of ASC50, a Potential Best-in-Class Oral Small Molecule IL-17 Inhibitor
levels, which continued until day 7 for higher doses of ASC50.- ASC50 demonstrated a dose-proportional pharmacokinetic profile from 10 mg to 600 mg in single ascending dose study in healthy participants.- ASC50 was safe and well tolerated at all dose levels.-
More news about: Ascletis Pharma Inc.
Dec 15, 2025, 04:00 ET 歌禮宣佈有望成為同類最佳口服小分子IL-17抑制劑ASC50美國I期研究取得積極的頂線結果
ASC50為歌禮自主研發的口服小分子IL-17靶向抑制劑，IL-17在銀屑病等多種自身免疫及炎症性疾病中已獲充分的生物學驗證並具備成熟商業價值。ASC50是一種新化學實體（NCE），擁有美國和全球化合物專利保護，專利保護期至2043年（不含潛在的專利延期）。
More news about: 歌禮製藥有限公司
Dec 10, 2025, 09:32 ET DNV RECEIVES CMS APPROVAL FOR NEW AMBULATORY SURGERY CENTERS ACCREDITATION PROGRAM
2025 /PRNewswire/ -- DNV is expanding its highly regarded healthcare accreditation service to the fast-growing ambulatory surgery center (ASC) sector. The new NIAHO® ASC Accreditation Program today received official approval from the US Centers for Medicare and Medicaid Services (CMS).
More news about: DNV
Dec 10, 2025, 09:08 ET DNV LAUNCHES ACCREDITATION FOR AMBULATORY SURGERY CENTERS
and continuous improvement to the ASC domain," added Alex Imperial, VP & Regional Manager, Supply Chain and Product Assurance Americas at DNV.DNV's ASC accreditation is highly scalable and adaptable. It recognizes the diversity of patient populations and ASC models, including those participating
More news about: DNV
Dec 10, 2025, 04:15 ET Ascletis Announces China National Medical Products Administration Acceptance of New Drug Application for Denifanstat (ASC40), a First-in-Class FASN Inhibitor for Acne Treatment
All denifanstat (ASC40)-related treatment-emergent adverse events (TEAEs) were mild (Grade 1) or moderate (Grade 2). There were no denifanstat (ASC40)-related Grade 3 or 4 TEAEs and no denifanstat (ASC40)-related serious adverse events (SAEs). There were no denifanstat (ASC40)-related permanent treatment
More news about: Ascletis Pharma Inc.